Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00763360 · ClinicalTrials.gov registry record · Phase 4

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

A Phase 4 study of Cataract, sponsored by Alcon Research.

Completed
Registry status
Phase 4
Development phase
184
Enrollment target
1
Study location

NCT00763360: Completed Phase 4 study of Cataract, sponsored by Alcon Research.

NCT00763360 is a Phase 4 study of Cataract that has completed, run by Alcon Research. The registered enrollment target is 184 participants, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00763360, a Phase 4 study of Cataract, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 4
Development phase
184 participants
Enrollment target
1
Study location

Study Summary

The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.

Primary Outcome

Change in endothelial cell count compared to baseline. Endothelial cell count peformed by counting of cells on photographic image of endothelium.

Conditions Studied

Interventions

  • DEVICE DisCoVisc®
  • DRUG Healon
  • DRUG Amvisc Plus

Study Locations (1)

Texas

  • Alcon Call Center - Fort Worth

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2008-05
Phase Phase 4
Alcon Research

275 total trials

What the finished NCT00763360 record still lists

NCT00763360 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (19% lower).

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 3 interventions - of which DisCoVisc® is the first listed.

NCT00763360 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00763360 about?

NCT00763360 is a clinical study titled "To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.". The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.

What is the current status of trial NCT00763360?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2008-05.

What conditions does trial NCT00763360 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT00763360?

The interventions under investigation include: DisCoVisc® (DEVICE), Healon (DRUG), Amvisc Plus (DRUG).

Who is sponsoring clinical trial NCT00763360?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00763360 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00763360's enrollment target sits among peer trials

184 28th of 83 higher than 56 of 83 other Cataract trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03903510 · 184 participants · NA

    Virtual Reality During Pediatric Cast Removal

  • NCT04020510 · 184 participants · Phase 4

    Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

  • NCT04135846 · 184 participants · Phase 2

    Alpha-1 Blockade for Alcohol Use Disorder (AUD)

  • NCT04396873 · 184 participants · Phase 1

    PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00763360, the US trial registry maintained by the National Library of Medicine. NCT00763360 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.